Putting the Pieces in Place: The Impact of Recent Pathophysiology Insights and Emerging Therapeutic Strategies to Address Unmet Treatment Needs in Eosinophilic Esophagitis (EoE)

 

 

PROGRAM OVERVIEW

Eosinophilic esophagitis (EoE) is not only diagnostically challenging, but patients with EoE face high healthcare costs, suboptimal outcomes, poor quality of life and a lack of efficacious therapies. While the standard of care comes with important limitations, recent insights into the pathophysiology of this esophageal disease have led to new and emerging biologic therapies with the potential to improve patient outcomes. The unmet treatment needs and unique challenges of EoE for both clinicians and patients, combined with recent advances in therapeutic options, highlight the critical need for clinicians to understand how to integrate these new agents in clinical treatment paradigms.

This interactive educational program will summarize the criteria and methodologies required to accurately diagnose EoE, while outlining updated guidelines to ensure optimal treatment. Recent clinical evidence will be reviewed supporting the role of emerging biologic agents in addressing current EoE care gaps, and patient case scenarios will illustrate the utility of these agents in clinical practice.

 

FACULTY

Ikuo Hirano, MD  (Program Chair)
Director, Esophageal Center at
Northwestern University
Feinberg School of Medicine
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

 

Edmond S. Chan MD, FRCPC, FCSACI, FAAAAI
Head, Division of Allergy & Immunology
Department of Pediatrics
Clinical Professor, The University of British Columbia
Clinical Investigator, BC Children’s Hospital Research Institute
BC Children’s Hospital
Vancouver, British Columbia

 

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

 

Release date: September 29, 2021
Expiration date: September 29, 2022
Estimated time to complete activity: 1 hour

 

TARGET AUDIENCE

This educational activity has been designed to meet the needs of gastroenterologists, allergists, immunologists, pediatric gastroenterologists, pediatric allergists/immunologists, specialty nurse practitioners, and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Summarize criteria and diagnostic tests to accurately diagnose EoE in a timely manner
  • Interpret the recently updated guidelines for the treatment and management of EoE
  • Articulate the latest Insights into pathophysiology on therapeutic strategies to address the unmet needs in EoE
  • Evaluate the utility of biologic agents in overcoming limitations of available treatment and in addressing the pathophysiology of EoE
  • Employ patient-centered approaches to improve outcomes in EoE
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2021 through September 29, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Ikuo Hirano, MD
Consulting Fees – Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/Bristol Myers Squibb, Eli Lilly, EsoCap Biotech, Gossamer Bio, Parexel, Regeneron, Sanofi, Shire/Takeda
Contracted Research – Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/Bristol Myers Squibb, Regeneron, Shire, Takeda

Edmond S. Chan MD, FRCPC, FCSACI, FAAAAI
Contracted Research – DBV Technologie
Consulting Fees – Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Consulting Fees – Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb
Contracted Research – Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Danone

The following project managers/planners: Donna Fausak and Maria Rovere, MTSC,  reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Continue to Pretest